Engineered immune cells take on childhood arthritis and autoimmune diseases

NCT ID NCT07184450

Recruiting now Disease control Sponsor: Chongqing Precision Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times

Summary

This study is testing a new treatment using specially engineered immune cells (CAR-T cells) in children aged 5 and older with severe rheumatic diseases like juvenile dermatomyositis, arthritis, systemic sclerosis, and Sjögren's syndrome that haven't improved with standard therapies. The treatment targets two proteins on faulty immune cells to calm the overactive immune system. The main goals are to check safety and see if it can reduce disease activity within six months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Children's Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

JUVENILE DERMATOMYOSITIS (JDM) POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS PRIMARY SJOGREN'S SYNDROME SYSTEMIC SCLEROSIS (SSC) SYSTEMIC SCLEROSIS (SSC)